These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18220499)

  • 41. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
    Boonen S; Laan RF; Barton IP; Watts NB
    Osteoporos Int; 2005 Oct; 16(10):1291-8. PubMed ID: 15986101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insights into the bisphosphonate holiday: a preliminary FTIRI study.
    Boskey AL; Spevak L; Ma Y; Wang H; Bauer DC; Black DM; Schwartz AV
    Osteoporos Int; 2018 Mar; 29(3):699-705. PubMed ID: 29204959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
    Ikeda T; Maruyama K; Kaji H; Akagi M
    Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in treatment of glucocorticoid-induced osteoporosis.
    Hsu E; Nanes M
    Curr Opin Endocrinol Diabetes Obes; 2017 Dec; 24(6):411-417. PubMed ID: 28857847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.
    Devogelaer JP
    Drug Saf; 1998 Aug; 19(2):141-54. PubMed ID: 9704250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Osteoporosis: trials and tribulations.
    Seeman E
    Am J Med; 1997 Aug; 103(2A):74S-87S; discussion 87S-89S. PubMed ID: 9302899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of alendronate after 5 years of treatment.
    Erviti J; Gorricho J
    JAMA; 2007 May; 297(18):1979; author reply 1980-1. PubMed ID: 17488959
    [No Abstract]   [Full Text] [Related]  

  • 49. Use of alendronate after 5 years of treatment.
    Ott SM
    JAMA; 2007 May; 297(18):1979; author reply 1980-1. PubMed ID: 17488958
    [No Abstract]   [Full Text] [Related]  

  • 50. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 51. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.
    Donaldson MG; Palermo L; Ensrud KE; Hochberg MC; Schousboe JT; Cummings SR
    J Bone Miner Res; 2012 Aug; 27(8):1804-10. PubMed ID: 22492479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adherence to alendronate in male veterans.
    Hansen KE; Swenson ED; Baltz B; Schuna AA; Jones AN; Elliott ME
    Osteoporos Int; 2008 Mar; 19(3):349-56. PubMed ID: 17898921
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic antiosteoporotic effect of Lepidium sativum and alendronate in glucocorticoid-induced osteoporosis in Wistar rats.
    Elshal MF; Almalki AL; Hussein HK; Khan JA
    Afr J Tradit Complement Altern Med; 2013; 10(5):267-73. PubMed ID: 24311835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alendronate in the treatment of osteoporosis: a review of the clinical trials.
    Siris E
    J Womens Health Gend Based Med; 2000; 9(6):599-606. PubMed ID: 10957748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of alendronate on bone mineral density in Puerto Rican males with osteoporosis.
    Martinó A; Rosa J; Guzmán J; Ramírez M
    P R Health Sci J; 2005 Jun; 24(2):131-5. PubMed ID: 16116930
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis.
    Kitazaki S; Mitsuyama K; Masuda J; Harada K; Yamasaki H; Kuwaki K; Takedatsu H; Sugiyama G; Tsuruta O; Sata M
    Aliment Pharmacol Ther; 2009 Feb; 29(4):424-30. PubMed ID: 19035979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
    Beauchesne MF; Miller PF
    Ann Pharmacother; 1999 May; 33(5):587-99. PubMed ID: 10369624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does a history of non-vertebral fracture identify women without osteoporosis for treatment?
    Ryder KM; Cummings SR; Palermo L; Satterfield S; Bauer DC; Feldstein AC; Schousboe JT; Schwartz AV; Ensrud K;
    J Gen Intern Med; 2008 Aug; 23(8):1177-81. PubMed ID: 18459010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.